• MJHLS Brand Logo

© 2026 MJH Life Sciences™ , Pharmaceutical Technology - Pharma News and Development Insights. All rights reserved.

Regulatory Roundup—August 2026

Published on: 

In August 2026, Heidi Overton was nominated for FDA commission, and a wave of oncology and neuro drugs were approved.

Advertisement

In August 2026, a new FDA commissioner was nominated by the White House; there was a variety of novel drug approvals spanning oncology to narcolepsy; and parallel moves from the United Kingdom's MHRA and Europe's EDQM were made to modernize standards—all set against tightened manufacturing scrutiny on both sides of the Atlantic.

FDA Leadership in Transition

On August 19, 2026, the White House nominated Heidi Overton,1 a physician with a Johns Hopkins doctorate and prior roles at the White House Domestic Policy Council and the America First Policy Institute, to fill the permanent FDA commissioner post left vacant since Marty Makary's May resignation, after Acting Commissioner Kyle Diamantas reportedly turned the job down more than once. The nomination arrives as FDA works through a roughly 20% staffing reduction, and Senate confirmation is not guaranteed.

Drug Pricing Takes Center Stage

The White House announced what it called the largest annual drop in prescription drug prices in more than 60 years, in August.2 The administration credits Most Favored Nation pricing deals with 17 manufacturers covering roughly 86% of the branded market, alongside the TrumpRx platform (cited as generating $700 million in patient savings) and GLP-1 prices falling from over $1000 a month to as low as $149. The release reports prescription drug prices down 3.9% since the administration began and falling every month in 2026, with the Department of Veterans Affairs citing $10 billion in pharmaceutical savings for the fiscal year.

FDA Novel Drug Approvals in August

The FDA has approved 35 novel drugs approved so far in 2026, spanning oncology, immunology, infectious disease, and rare genetic disorders.3 Several of these were approved in August.

In oncology, the FDA granted accelerated approval to Replimune's Tudriqev (vusolimogene oderparepvec-wtpg) in combination with nivolumab for advanced cutaneous melanoma that has progressed on PD-1 therapy, a population where, as IGNYTE study investigator Michael Wong noted, patients “have few options after anti-PD-1 therapy and face high morbidity.”4 Trial data released by the FDA put the objective response rate at 24.2% among 91 evaluable patients, with a median duration of response of 14.1 months; confirmatory trials are required to maintain approval.5

The FDA also cleared Rasonque (daraxonrasib) as the first RAS-targeted therapy for metastatic pancreatic adenocarcinoma, arriving 6.5 months ahead of schedule after a 500-patient trial showed median overall survival of 13.2 months versus 6.7 months on chemotherapy. Center of Excellence Director, Angelo de Claro, called the results “unprecedented” for an area of high unmet need.6

Bristol-Myers Squibb also picked up accelerated approval for Zenbexus (iberdomide) in combination with daratumumab, hyaluronidase-fihj, and dexamethasone for relapsed/refractory multiple myeloma, based on EXCALIBER-RRMM data showing a 41% MRD-negative complete response rate versus 21% for the comparator arm; the drug carries boxed warnings and restricted REMS distribution given embryo-fetal toxicity risk.7

Neurology and infectious disease also saw approvals for new drugs. The FDA approved Orzeyful (oveporexton), the first orex in receptor agonist for narcolepsy type 1, which the Center for Drug Evaluation and Research (CDER) Psychiatry Division Director Tiffany Farchione described as “the first medicine that impacts the underlying biology of the disease.”8

Lantheus won approval for Tauklarify, a tau PET imaging agent that Massachusetts General Hospital's Keith Johnson said is “essential for increasing our understanding of potential disease impacts” in Alzheimer's evaluation, though the approval excludes non-Alzheimer's tauopathies.9

Moderna secured approval for mFlusiva, the first messenger RNA-based flu vaccine, for adults 50 and older, contingent on a confirmatory trial in the oldest cohort, after a 40,000-plus-participant trial showed roughly 27% higher effectiveness than a standard-dose comparator.10

Separately, the FDA approved Tivicay PD for HIV-positive newborns from birth through four weeks based on the IMPAACT 2023 study,11 and approved Lisraya (brepocitinib) as the first oral therapy for adult dermatomyositis, which FDA's Nikolay Nikolov said is “giving patients and their healthcare providers an approved oral therapy.”12

Teva's ecopipam new drug application for pediatric Tourette syndrome was accepted with priority review, targeting an action date in early 2027; EVP Eric Hughes called it potentially “the first novel mechanism of action in more than 50 years” for the condition.

New and Revised FDA Guidance

The FDA also moved on several policy fronts. A draft revision on choosing between an abbreviated new drug application and a 505(b)(2) application is open for comment through October 19, updating 2019 guidance on the same question.14

A draft guidance on container closure systems for human drugs and biologics, including combination product components is open for comment through October 13.15

"What stands out in the draft guidance is the emphasis on understanding container closure integrity as part of the overall manufacturing process rather than as a standalone compliance exercise. For sterile drugs and biologics, especially in high-value injectable formats, manufacturers need reliable ways to detect defects that may compromise package integrity before products reach patients. Technologies such as automated vision inspection and deterministic CCIT methods can provide a deeper understanding of process performance, helping manufacturers move from reactive testing toward real process control. That's where we see the industry heading, and the guidance aligns well with that direction," Daniele Ansaldi, Technical Manager, Inspection Machines for Antares Vision Group, told PharmTech.

And Deborah Smook, VP of Marketing & Business Development for TurboFil Packaging Machines LLC, provided her take on the guidance, telling PharmTech: “FDA’s new draft guidance updates container closure recommendations that have been in place for more than 25 years, reflecting advances in drug-delivery systems, combination products, materials science, and testing. Of particular relevance to equipment manufacturers such as TurboFil, the updated guidance places more explicit emphasis on how manufacturing and assembly processes can affect container closure integrity and device performance, including the control and validation of parameters such as capping, stoppering, and other closure operations. We believe this reinforces the value of involving filling and assembly equipment suppliers early in product development, when component specifications, tolerances and critical process parameters can be addressed before the manufacturing process is finalized.”

The FDA separately proposed potency assessment standards for active immunotherapy products, supplementing 2023 guidance on cellular and gene therapies, with comments due November 18, 2026.16

On compounding, the FDA flagged at least 30 adverse events tied to injectable glutathione made with dietary-supplement-grade material from a single lot, prompting recalls at two Texas pharmacies and a reminder that supplement-grade ingredients aren’t fit for injectable use.17

In a move tied to the administration's broader pricing push, the FDA released 55 new or revised product-specific guidances to support generic-drug development for more than 30 products that currently lack generic competition.18

And the FDA finalized its long-pending guidance on therapeutic equivalence evaluations and Orange Book TE codes, closing out a draft that had been open since 2022.19

Manufacturing Compliance: FDA-Issued Warning Letters

FDA enforcement activity was active throughout August. Tianjin Kilo Pharmaceutical was cited for distributing APIs without adequate process validation, incomplete batch records, and missing stability testing.20 K.C. Pharmaceuticals drew scrutiny for continuing sterile manufacturing after repeated media-fill failures and inadequate visual inspection and has since initiated a voluntary recall.21

Suretec Innovations failed, according to the FDA, to test incoming components and did not investigate out-of-limit microbial results.22 Eugia Pharma Specialities faced findings on aseptic-processing design and environmental monitoring, with the FDA noting similar deficiencies across multiple company sites.23 Auriga Research was cited for incomplete laboratory records and a pattern of retesting until passing results were obtained without documented justification.24 And Safrel Pharmaceuticals was flagged for inadequate quality-unit oversight, improper product segregation, and gaps in distribution traceability.25

Together, the letters underscore the FDA’s continued focus on aseptic technique, data integrity, and quality-unit authority as recurring inspection themes.

MHRA Advances Access and Safety

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) approved Deciphera's vimseltinib (Romvimza) for tenosynovial giant cell tumor, with Executive Director Julian Beach noting it “provides a new treatment option for patients with TGCT.”26

Because of public concern, MHRA reaffirmed vaccine safety, with Chief Safety Officer Alison Cave stating plainly that “there is no evidence that vaccines cause autism in children.”27 The agency also staked out its regulatory position on microbiome-based medicinal products, confirming they fall under existing UK medicines law—an area Beach called “one of the most interesting and fast-moving areas in medicine today.”28

On the approvals side, the UK became the first country in Europe to authorize Eli Lilly's oral orforglipron (Foundayo) for weight management and type 2 diabetes,29 with Beach noting MHRA was “pleased to be the first regulator in Europe to authorize this tablet,” though NHS availability awaits NICE evaluation.

MHRA also approved Novartis's remibrutinib (Rhapsido) for chronic spontaneous urticaria via the International Recognition Procedure, based on trials in 925 adults.30 Separately, the Innovative Licensing and Access Pathway granted Innovation Passports to an investigational hepatocellular carcinoma therapy and a dementia-with-Lewy-bodies candidate, with MHRA's James Pound noting the program "helps developers engage with the regulatory system earlier and more effectively"; the next application window runs through November 4.31

European Pharmacopoeia and EDQM standards

The European Directorate for the Quality of Medicines & HealthCare (EDQM), which publishes the European Pharmacopoeia, had a busy month of standards work. The directorate updated its guidance for electronic CEP submissions, clarifying eCTD validation report formatting and how module 3 changes should be documented.32 It also published a new general chapter on procoagulant activity testing for immunoglobulin preparations, describing 3 detection methods ahead of enforcement in July 2027.33

In an animal-welfare move, EDQM reactivated its Botulinum Toxin Working Party to begin phasing the mouse LD50 assay out of botulinum toxin monographs, continuing the agency's 3Rs commitment.34 A revised macrogols monograph is open for public comment through September 30, introducing separate limits for ethylene glycol and diethylene glycol contamination across 12 macrogol grades.35

EDQM also published results of a collaborative study establishing replacement heparin sodium reference batches under its Biological Standardisation Programme,36 and issued revised guidance on using one CEP to describe a material in another CEP application, aligning with CEP 2.0 and EMA quality-working-party principles.37

References

  1. What does Overton's FDA nomination mean for drug reviews? PharmTech. August 2026. https://www.pharmtech.com/view/what-does-overtons-fda-nomination-mean-for-drug-reviews-
  2. President Trump delivers largest prescription drug price drop in over 60 years. Press release. The White House. August 17, 2026. https://www.whitehouse.gov/releases/2026/08/president-trump-delivers-largest-prescription-drug-price-drop-in-over-60-years/
  3. Novel drug approvals for 2026. FDA. Updated August 27, 2026. Accessed August 31, 2026. https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026
  4. FDA approves new engineered viral immunotherapy for patients with treatment-resistant advanced melanoma. Press release. FDA. August 6, 2026. Accessed August 7, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-new-engineered-viral-immunotherapy-patients-treatment-resistant-advanced-melanoma
  5. FDA grants accelerated approval to vusolimogene oderparepvec-wtpg in combination with nivolumab for melanoma. August 6, 2026. FDA. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma
  6. U.S. FDA approves Revolution Medicines’ RAS(ON) inhibitor daraxonrasib. Press release. Revolution Medicines. August 26, 2026. https://ir.revmed.com/news-releases/news-release-details/us-fda-approves-revolution-medicines-rasonquetm-daraxonrasib
  7. FDA Grants Accelerated Approval to Iberdomide, Daratumumab and Hyaluronidase-fihj, and Dexamethasone. FDA. August 13, 2026. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-iberdomide-daratumumab-and-hyaluronidase-fihj-and-dexamethasone
  8. FDA approves first drug to treat the full range of narcolepsy type 1 symptoms. US Food and Drug Administration. News Release. August 5, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms
  9. Lantheus announces FDA approval of TAUKLARIFY™ (florquinitau F 18) injection. GlobeNewswire. Press Release. August 14, 2026. https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-announces-fda-approval-tauklarifytm-florquinitau-f-18
  10. Moderna Receives U.S. FDA Approval for Influenza Vaccine mFLUSIVA. Press release. Moderna. August 5, 2026. https://feeds.issuerdirect.com/news-release.html
  11. FDA Approves Drug to Treat HIV Infection in Newborns. FDA. August 25, 2026. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-treat-hiv-infection-newborns
  12. FDA Approves First Oral Drug Indicated to Treat Dermatomyositis in Adults. Press release. FDA. August 27, 2026. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-drug-indicated-treat-dermatomyositis-adults
  13. Ecopipam's D1 Receptor Approach Signals Pediatric Neuroscience Pathway. PharmTech. August 2026. https://www.pharmtech.com/view/ecopipams-d1-receptor-approach-signals-pediatric-neuroscience-pathway
  14. Determining Whether to Submit an ANDA or a 505(b)(2) Application. Draft guidance. FDA. August 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/determining-whether-submit-anda-or-505b2-application-0
  15. Container Closure Systems for Human Drugs and Biological Products. Draft guidance. FDA. August 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/container-closure-systems-human-drugs-and-biological-products
  16. Potency Assessment of Active Immunotherapy Products; Draft Guidance for Industry; Availability. Federal Register. FDA. August 20, 2026. https://www.federalregister.gov/documents/2026/08/20/2026-16960/potency-assessment-of-active-immunotherapy-products-draft-guidance-for-industry-availability
  17. FDA Reminds Compounders Not to Use Dietary Supplement-Grade Glutathione for Injectables. FDA. August 27, 2026. https://www.fda.gov/drugs/human-drug-compounding/fda-reminds-compounders-not-use-dietary-supplement-grade-glutathione-injectables
  18. FDA Publishes New Product-Specific Guidances to Facilitate Generic Drug Development. FDA. August 21, 2026. https://www.fda.gov/drugs/drug-alerts-and-statements/fda-publishes-new-product-specific-guidances-facilitate-generic-drug-development
  19. Evaluation of Therapeutic Equivalence. Final guidance. FDA. August 2026. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/evaluation-therapeutic-equivalence
  20. Warning Letter: Tianjin Kilo Pharmaceutical Sci-tech Co., Ltd. FDA. August 6, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/tianjin-kilo-pharmaceutical-sci-tech-co-ltd-731761-08062026
  21. Warning Letter: K.C. Pharmaceuticals, Inc. FDA. August 12, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kc-pharmaceuticals-inc-729870-08122026
  22. Warning Letter: Suretec Innovations, LLC. FDA. August 13, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/suretec-innovations-llc-730122-08132026
  23. Warning Letter: Eugia Pharma Specialities Limited. FDA. August 13, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/eugia-pharma-specialities-limited-730469-08132026
  24. Warning Letter: Auriga Research Pvt. Ltd. FDA. August 12, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/auriga-research-pvt-ltd-730694-08122026
  25. Warning Letter: Safrel Pharmaceuticals LLC. FDA. August 7, 2026. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/safrel-pharmaceuticals-llc-730520-08072026
  26. Vimseltinib (Romvimza) Approved for Use in Adults to Treat Tenosynovial Giant Cell Tumours. MHRA. August 14, 2026. https://www.gov.uk/government/news/vimseltinib-romvimza-approved-for-use-in-adults-to-treat-tenosynovial-giant-cell-tumours
  27. MHRA Reaffirms the Safety of Childhood Vaccination. MHRA. August 12, 2026. https://www.gov.uk/government/news/mhra-reaffirms-the-safety-of-childhood-vaccination
  28. MHRA Sets Out Position on Regulation of Microbiome-Based Medicinal Products. MHRA. August 18, 2026. https://www.gov.uk/government/news/mhra-sets-out-position-on-regulation-of-microbiome-based-medicinal-products
  29. UK First in Europe to Authorise Orforglipron for Weight Management and Type 2 Diabetes. MHRA. August 10, 2026. https://www.gov.uk/government/news/uk-first-in-europe-to-authorise-orforglipron-for-weight-management-and-type-2-diabetes
  30. MHRA Approves Remibrutinib for Adults with Chronic Spontaneous Urticaria. MHRA. August 5, 2026. https://www.gov.uk/government/news/mhra-approves-remibrutinib-for-adults-with-chronic-spontaneous-urticaria
  31. The Innovative Licensing and Access Pathway Grants Innovation Passports to Investigational Products for Cancer and Dementia. MHRA. August 4, 2026. https://www.gov.uk/government/news/the-innovative-licensing-and-access-pathway-grants-innovation-passports-to-investigational-products-for-cancer-and-dementia
  32. Update to the Guidance for Electronic Submissions of CEP Applications. EDQM. August 19, 2026. https://www.edqm.eu/en/-/update-to-the-guidance-for-electronic-submissions-of-cep-applications
  33. New General Chapter on Procoagulant Activity Testing of Immunoglobulin Preparations Soon to Be Published in the Ph. Eur. EDQM. August 10, 2026. https://www.edqm.eu/en/-/new-general-chapter-on-procoagulant-activity-testing-of-immunoglobulin-preparations-soon-to-be-published-in-the-ph.-eur.
  34. Phasing Out the Mouse LD50 Assay. EDQM. August 7, 2026. https://www.edqm.eu/en/-/phasing-out-the-mouse-ld50-assay
  35. New Control of Ethylene Glycol and Diethylene Glycol in Macrogols 1444 Published for Comment. EDQM. August 4, 2026. https://www.edqm.eu/en/-/new-control-of-ethylene-glycol-and-diethylene-glycol-in-macrogols-1444-published-for-comment
  36. Publication of a Collaborative Study on Ph. Eur. Heparin Sodium BRP Batches 5 and 6. EDQM. August 27, 2026. https://www.edqm.eu/en/-/publication-of-a-collaborative-study-on-ph.-eur.-heparin-sodium-brp-batches-5-and-6
  37. Revised Guidance About the Use of a CEP to Describe a Material Used in an Application for Another CEP. EDQM. August 27, 2026. https://www.edqm.eu/en/-/revised-guidance-about-the-use-of-a-cep-to-describe-a-material-used-in-an-application-for-another-cep

US Guidance Documents for August 2026

FDA Warning Letters for August 2026

US Drug Approvals in August 2026

Upcoming September 2026 Meetings and Events

Related Content:

PharmTech VideosQuality SystemsDrug DevelopmentManufacturing
From Detection to Prediction: Analytical Approaches for Nitrosamine Risk
Lilly's $2.875B Merida Deal Has Implications for Autoantibody Diseases
What to Know from the FDA’s End of August Activity